fda warning letter bpc-157 dietary supplement unapproved new drug FDA Issues Warning Letters to Companies Selling Supplements that Claim to Treat Cardiovascular F.D.A. Panel's Vote on Peptides

Studies show improvements in cholesterol levels, triglycerides, and inflammatory markers

The occurrence of administration-site reactions in the cagrilintide groups was dose-dependent and higher than in the liraglutide 3.0 mg or pooled placebo groups

Simoens et al

This indicates that while higher doses may have some impact on kidney function, this effect is reversible and does not occur at lower, more commonly used doses

According to the Texas Board of Pharmacy, a May 2022 inspection of the facility led to a mandate that the pharmacy immediately cease production of compounded sterile preparations due to pharmacist training failures, insufficient cleaning, and insufficient recordkeeping